Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.7%

32 terminated/withdrawn out of 95 trials

Success Rate

51.5%

-35.1% vs industry average

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

109%

37 of 34 completed trials have results

Key Signals

11 recruiting37 with results19 terminated13 withdrawn

Enrollment Performance

Analytics

Phase 1
45(48.4%)
Phase 2
42(45.2%)
Phase 3
5(5.4%)
Early Phase 1
1(1.1%)
93Total
Phase 1(45)
Phase 2(42)
Phase 3(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (95)

Showing 20 of 95 trials
NCT04442022Phase 2Active Not Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Role: lead

NCT04925193Phase 2Active Not Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT04414475Phase 2Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Role: lead

NCT02227251Phase 2Active Not Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Role: lead

NCT04562389Phase 3Active Not Recruiting

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Role: lead

NCT05611931Phase 3Active Not Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: lead

NCT07832227Phase 2Not Yet Recruiting

Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial

Role: collaborator

NCT04661137Phase 2Recruiting

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Role: collaborator

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT07479979Phase 1Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT06399640Phase 1Recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Role: collaborator

NCT02343042Phase 1Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Role: lead

NCT04562870Phase 2Active Not Recruiting

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

Role: lead

NCT07200102Phase 1Recruiting

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Role: collaborator

NCT03627403Phase 2Terminated

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Role: collaborator

NCT02091245Phase 1Active Not Recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Role: collaborator

NCT04898894Phase 1Active Not Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Role: collaborator

NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: lead

NCT07447817Phase 2Not Yet Recruiting

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Role: collaborator

NCT07215832Unknown

Karyopharm Expanded Access Program for Selinexor

Role: lead